PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1629212
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1629212
Glucose tolerance test market size was valued at USD 26,920.43 Million in 2023, expanding at a CAGR of 6.60% from 2024 to 2032.
A glucose tolerance test (GTT) is a diagnostic tool used to evaluate the body's response to sugar intake, primarily for diagnosing diabetes. It includes an oral glucose tolerance test (OGTT), where blood glucose levels are measured before and after consuming a glucose solution. High glucose levels may indicate impaired sugar absorption by body cells. A simpler version, the glucose challenge test, involves a single blood test following glucose intake.
Glucose Tolerance Test Market- Market Dynamics
Increasing rate of diabetes worldwide to propel market demand
The growing prevalence of diabetes among people across the globe is the major factor driving the growth of the global glucose tolerance test market. For instance, the global incidence of diabetes is expected to rise to 783 million by 2045, up from 537 million in 2021. Besides, increasing awareness of diabetes mellitus in densely populated regions, combined with significant investments in the design and development of large-scale diagnostic solutions, is expected to fuel market growth. However, high costs and restricted access to medical services in underdeveloped regions may hamper the market growth. On the contrary, the integration of deep learning and robotics in the diagnostic industry and increased government funding for research and development in diabetes therapeutics & diagnostics are predicted to provide massive growth opportunities for the market during the forecast period.
Glucose Tolerance Test Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.60% over the forecast period (2024-2032)
Based on product type segmentation, blood glucose test kit was predicted to show maximum market share in the year 2023
Based on disease indication segmentation, diabetes hypoglycemia was the leading segment in 2023
On the basis of region, the North America glucose tolerance test market was the leading revenue generator in 2023
The Global Glucose Tolerance Test Market is segmented on the basis of Product Type, Disease Indication, End User, and Region.
The market is divided into four categories based on product type: blood glucose testing kit, smart sensors, meters, and others. The blood glucose testing kit sector dominates the market. Advancements in smart sensor technology and seamless IoT connectivity are driving the market growth.
The market is divided into two categories based on end user: homecare settings, hospitals & clinics, diagnostic centers, and others. The hospitals & clinics sector dominates the market and is likely to maintain its dominance during the forecast period. This is mainly due to the high patient volume they handle and the availability of advanced diagnostic tools for accurate and efficient glucose tolerance testing.
Glucose Tolerance Test Market- Geographical Insights
Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.
The market is propelled by growing awareness and efforts for early diabetes detection. Companies are prioritizing strategic collaborations to enhance research and develop advanced diagnostic solutions. To stay competitive, players are investing in cutting-edge technologies, like digital health integration, for better glucose monitoring. Additionally, expanding global presence through mergers and acquisitions is a key focus, as it helps diversify product lines and reach untapped markets, boosting their overall competitiveness and market influence.
In August 2024, DirectSens has introduced the XpressGT RUO kit for diagnosing conditions like Gestational Diabetes, Endometriosis, Insulin Resistance, and Liver Disease. Compatible with standard clinical analyzers, XpressGT provides results in just 8 minutes, measuring 2-hydroxybutyrate (2-HB) levels in venous blood, which, when elevated, indicate potential endocrine and metabolic disorders.